An anti-seizure medication acts on unexpected molecular targets, according to a Northwestern Medicine study published in the Journal of Neuroscience.
Designed to target AMPA receptors in the brain, the medication—called perampanel—turns out to also modulate kainate receptors, according to Geoffrey Swanson, Ph.D., professor of Pharmacology and senior author of the study.
